

JUL 16 2004

510(k) Summary

Safety and Effectiveness

Q•Cap™ Needle-Free Reconstitution 13mm Vial Adapter

[per FD&C Act, Section 513 (l)(3)(A) and 21CFR Section 807.3]

Applicant:	Bioject Medical Technologies Inc. 211 Somerville Road Bedminster, New Jersey 07921
Contact Person:	Laurence A. Potter Director, Regulatory Affairs
Telephone:	908-470-2800
Fax:	908-470-1728
Email:	lpotter@bioject.com
Manufacturer:	Bioject, Inc. 20245 S.W. 95 th Avenue Tualatin, Oregon 97062
Establishment Registration No.	3023012
Sterilization Site:	Dravon Medical 11465 SE Highway 212 Clackamas, Oregon
Establishment Registration No.	3021634
Device Trade Name:	Q•Cap™ Needle-Free Reconstitution 13mm Vial Adapter
Device Classification:	Class II, Special Controls
Common Name:	Vial Adapter
Regulatory Status:	<div>Product Code: LHI</div> <div>C.F.R. Regulation No.: 880.5440</div> <div>Description: Intravascular Administration Set</div>
Medical Specialty	General Hospital and Personal Use Devices

510(k) Summary Safety and Effectiveness

Q•Cap™ Needle-Free Reconstitution 13mm Vial Adapter (con't)

Indications for Use:

The Q•Cap™ Needle-Free Reconstitution 13mm Vial Adapter is intended to allow needle-free withdrawal, reconstitution and transfer of Repronex® (menotropins for injection, USP) and/or Bravelle® (urofollitropin for injection, purified) and diluent from vials into an injection syringe for administration.

Predicate Device(s):

Bioject Needle-Free Vial Adapter (13mm) K963012
Bioject, Incorporated, Portland, Oregon

Reconstitution Kit & Vial Connector K010623
Bioject, Incorporated, Portland, Oregon
*For use with Serono, Inc.'s, Serojet™ and Serostim®
Human Growth Hormone Starter Kits.*

Ferring Pharmaceutical's Repronex® (menotropins for injection, USP) was previously approved by FDA's Center for Drug Evaluation and Research (CDER) under NDA 21-047.

Ferring Pharmaceutical's Bravelle® (urofollitropin for injection, purified) was previously approved by FDA's Center for Drug Evaluation and Research (CDER) under NDA 21-484.

Device Design and Performance:

The device which is the subject of this Notification is a sterile, injection molded component, which will be included into Ferring Pharmaceutical's Repronex® and Bravelle® drug kits to assist in needle-free reconstitution of these lyophilized drugs for injection.

The Vial Adapter component's physical design, description and performance are identical to that of a previously cleared device, Bioject Reconstitution Kit & Vial Connector (K010623). Packaging and sterilization of the Vial Adapter are identical to that of a previously cleared devices, Bioject Needle-Free Vial Adapter, (13mm); K963012.

The biocompatibility of the clear polycarbonate component (General Electric Lexan® 144R), is demonstrated for both Cytotoxicity and for each specific Ferring fertility drug used for reconstitution. No color additives are present in this component.

Ethylene oxide sterilization, ETO residual testing, and LAL Pyrogen testing support additional product safety. No other safety issues have been identified for the device component subject to this Notification.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUL 16 2004

Mr. Laurence A. Potter
Director, Regulatory Affairs
Bioject Medical Technologies, Incorporated
211 Somerville Road
Route 202 North
Bedminster, New Jersey 07921

Re: K041564

Trade/Device Name: Q Cap™ Needle-Free Reconstitution 13mm Vial Adapter
Regulation Number: 21 CFR 880.5440,
Regulation Name: Intravascular Administration Set,
Regulatory Class: II
Product Code: LHI, FMF
Dated: June 8, 2004
Received: June 15, 2004

Dear Mr. Potter:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4618. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Chiu Lin", is written over the printed name.

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health


Enclosure

Statement of Indications for Use

510(k) Number (if known):

Device Name: Q•Cap™ Needle-Free Reconstitution 13mm Vial Adapter

Indications for Use: The Q•Cap™ Needle-Free Reconstitution 13mm Vial Adapter is intended to allow needle-free withdrawal, reconstitution and transfer of Repronex® (menotropins for injection, USP) and/or Bravelle® (urofollitropin for injection, purified) and diluent from vials into an injection syringe for administration.



Laurence A. Potter
Director, Regulatory Affairs


Date JUNE 8, 2004

Prescription Use X Or Over-the-Counter Use _____
(Per 21 CFR 801.109) (Optional Format 1-2-96)

36

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER
PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of Anesthesiology, General Hospital,
Infection Control, Dental Devices

510(k) Number: K041564